Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued

ELI LILLY & Co

2023-FY EPS reported $5.80 revenue$34,124,100,000

Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).
New Products (Mounjaro, Zepbound) generated $2.49B revenue, up $2.19B YoY; Growth Products $5.27B (+9%).
2024 guidance: revenue $40.4–41.6B; EPS $11.80–12.30; non-GAAP EPS $12.20–12.70.
Pipeline: Zepbound and Jaypirca approved; tirzepatide Phase 2 NASH met primary endpoint; Verzenio Phase 3 mCRPC failed.
Acquisitions of POINT Biopharma and Mablink Biosciences closed; dividend raised 15% for 6th consecutive year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELI LILLY & Co reported the quarter and year ended December 31, 2023 results: revenue $9,353.4, net income 2,189.6, EPS 2.42. Guidance initiated.

Period: the quarter and year ended December 31, 2023
Revenue: $9,353.4
Net income: 2,189.6
EPS: 2.42
Guidance: initiated
Result: reported results

Exact text from the filing

on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Fourth Quarter 2023 2022 % Change Revenue $ 9,353.4 $ 7,301.8 28% Net income – Reported 2,189.6 1,937.7 13% Earnings per share – Reported 2.42 2.14 13% Net income – Non-GAAP 2,249.4 1,893.1 19% Earnings per share – Non-GAAP 2.49

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.